Ekso Bionics (NASDAQ:EKSO) Now Covered by StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of Ekso Bionics (NASDAQ:EKSOGet Rating) in a research note issued to investors on Sunday. The firm set a “sell” rating on the stock.

Separately, HC Wainwright cut their price target on Ekso Bionics from $11.00 to $9.00 and set a “buy” rating on the stock in a research report on Friday, July 29th.

Ekso Bionics Stock Performance

NASDAQ EKSO opened at $2.20 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 7.48 and a current ratio of 8.16. Ekso Bionics has a fifty-two week low of $1.53 and a fifty-two week high of $5.17. The company has a market cap of $28.67 million, a P/E ratio of -2.22 and a beta of 1.77. The business’s 50 day moving average price is $2.07 and its 200-day moving average price is $2.18.

Ekso Bionics (NASDAQ:EKSOGet Rating) last released its earnings results on Thursday, July 28th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.01. The company had revenue of $3.47 million for the quarter, compared to the consensus estimate of $3.49 million. Ekso Bionics had a negative net margin of 94.39% and a negative return on equity of 35.11%. During the same quarter in the previous year, the firm earned ($0.26) EPS. Sell-side analysts predict that Ekso Bionics will post -1.04 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of EKSO. Golden State Wealth Management LLC bought a new stake in shares of Ekso Bionics in the 4th quarter worth $41,000. Renaissance Technologies LLC boosted its position in Ekso Bionics by 153.4% during the second quarter. Renaissance Technologies LLC now owns 44,606 shares of the company’s stock valued at $74,000 after purchasing an additional 27,006 shares during the last quarter. Finally, Essex Investment Management Co. LLC acquired a new stake in shares of Ekso Bionics in the first quarter worth about $484,000. Institutional investors own 12.47% of the company’s stock.

Ekso Bionics Company Profile

(Get Rating)

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Europe, the Middle east, Africa, the Asia Pacific, and internationally. The company operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.

Featured Stories

Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.